Unique ID issued by UMIN | UMIN000021694 |
---|---|
Receipt number | R000024740 |
Scientific Title | Single-institutional observational surveillance of nivolumab for previously treated with non-small cell lung cancer |
Date of disclosure of the study information | 2016/04/01 |
Last modified on | 2019/03/22 12:00:36 |
Single-institutional observational surveillance of nivolumab for previously treated with non-small cell lung cancer
observational study of nivolumab
Single-institutional observational surveillance of nivolumab for previously treated with non-small cell lung cancer
observational study of nivolumab
Japan |
non-small cell lung cancer
Pneumology |
Malignancy
NO
To investigate the predictive factor response with clinical characteristics
Efficacy
Exploratory
Not applicable
response rate
progression-free survival; overall survival; safety; predictive factor of prognosis and safety
Observational
Not applicable |
Not applicable |
Male and Female
All patients treated with nivolumab for previously treated with NSCLC from 2016
inadequate patients for nivolumab treatment
100
1st name | Yusuke |
Middle name | |
Last name | Okuma |
Tokyo Metropolitan Komagome Hospital
Department of Thoracic Oncology
113-8677
3-18-22, Honkomagome, Bunkyo, Tokyo, JAPAN
03-3823-2101
y-okuma@cick.jp
1st name | Yusuke |
Middle name | |
Last name | Okuma |
Tokyo Metropolitan Komagome Hospital
Department of Thoracic Oncology
113-8677
3-18-22, Honkomagome, Bunkyo, Tokyo, JAPAN
03-3823-2101
y-okuma@cick.jp
Tokyo Metropolitan Komagome Hospital
Tokyo Metropolitan Komagome Hospital
Self funding
Ethics committee of Tokyo Metropolitan Komagome Hospital
3-28-22, Honkomagome, Bunkyo, Tokyo
03-3823-2101
rinri@cick.jp
NO
2016 | Year | 04 | Month | 01 | Day |
https://www.ncbi.nlm.nih.gov/pubmed/30655989
Published
https://www.ncbi.nlm.nih.gov/pubmed/30655989
67
The patients who were treated with nivolumab as the standard of care were enrolled.
2019 | Year | 03 | Month | 22 | Day |
The patients who were treated with nivolumab as the standard of care were enrolled.
The patients who were treated with nivolumab as the standard of care were enrolled.
we have published in the articles
we have published in the articles
Main results already published
2016 | Year | 03 | Month | 12 | Day |
2016 | Year | 04 | Month | 01 | Day |
2016 | Year | 04 | Month | 01 | Day |
2017 | Year | 12 | Month | 31 | Day |
Case control study. We will assess clinical demographic, diagnosis, histological subtypes, treatment of nivolumab, clinical outcome (response, time-to-event), or laboratory data.
2016 | Year | 03 | Month | 30 | Day |
2019 | Year | 03 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024740
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |